IL2 and systemic lupus erythematosus: In ongoing clinical trials, the safety and efficacy of a human IL-2 mutein Fc fusion protein (Efavaleukin Alfa) to selectively stimulate Tregs is being evaluated in patients with GvHD (NCT03422627) and systemic lupus erythematosus (NCT03451422).